Objectives: Our previous studies indicated that highly selective κ opioid receptor agonists could protect the brain, indicating an important role of κ opioid receptor agonist in brain ischemia. In this study, we investigated the role and related mechanisms of κ opioid receptor agonists in brain ischemia in a middle cerebral artery occlusion mouse model. Design: Animal model. Setting: Laboratory. Subjects: The middle cerebral artery occlusion model was established by 120 minutes of ischemia followed by 24-hour reperfusion in male adult mice. Interventions: Various doses of salvinorin A, a highly selective and potent κ opioid receptor agonist, were administered intranasally 10 minutes after initiation of reperfusion. Norbinaltorphimine (2.5 mg/kg, IP) as a κ opioid receptor antagonist was administered in one group before administration of salvinorin A (50μg/kg) to investigate the specific role of κ opioid receptor. Measurements and Main Results: Infarct volume, κ opioid receptor expression, and Evans blue extravasation in the brain, and neurobehavioral outcome were determined. Immunohistochemistry and western blot were performed to detect the activated caspase-3, interleukin-10, and tumor necrosis factor-α levels to investigate the role of apoptosis and inflammation. κ opioid receptor expression was elevated significantly in the ischemic penumbral area compared with that in the nonischemic area. Salvinorin A reduced infarct volume and improved neurologic deficits dosedependently. Salvinorin A at the dose of 50 μg/kg reduced Evans blue extravasation, suggesting reduced impairment of the bloodbrain barrier and decreased the expression of cleaved caspase-3, interleukin-10, and tumor necrosis factor-α in the penumbral areas. All these changes were blocked or alleviated by norbinaltorphimine. Conclusions: κ opioid receptors were up-regulated and played a critical role in brain ischemia and reperfusion. κ opioid receptor activation could potentially protect the brain and improve neurologic outcome via blood-brain barrier protection, apoptosis reduction, and inflammation inhibition. (Crit Care Med 2016; 44:e1219-e1225) 
C erebral ischemia and reperfusion (IR) injury, one of the major components of stroke, as well as cardiac arrest and many other vascular disease processes, could cause irreversible motor and sensory deficits. Complex mechanisms are involved during brain IR injury. Using salvinorin A (SA), a highly selective and potent κ opioid receptor (KOR) agonist, we demonstrated that SA could dose-dependently dilate the pial artery, preserve artery autoregulation, and protect the brain in a piglet global cerebral ischemia model (1) (2) (3) . The potential neuroprotective effects of SA have not been well described in models of focal ischemia. One of the major pharmacologic properties of SA is that it is a fast-onset and shortacting agent that additionally can pass the blood-brain barrier (BBB) easily. Thus, SA could be a powerful tool to investigate the role of KOR in these pathologic conditions with very narrow therapeutics windows like brain ischemia. Although SA has limited potential for use in conscious humans because of its psychotropic effects, effectiveness in a mouse focal ischemia model could provide a basis for developing κ opioid agonists with less prominent side effects. In this study, we aimed to use SA to investigate the role of KOR agonist in a mouse focal cerebral ischemia model.
In this study, we investigated whether administration of KOR agonist SA could reduce cerebral infarction, protect BBB, and improve neurologic outcomes via specific KOR activation in a mouse middle cerebral artery occlusion (MCAO) model.
The expression of KOR and activated caspase-3 protein as an apoptotic marker and the levels of interleukin (IL)-10 and tumor necrosis factor (TNF)-α as the markers of inflammation were determined to elucidate their relationships. This study has significant clinical relevance for the following reasons: 1) opioids are commonly used in critically ill patients; 2) there is no neuroprotectant available in clinical practice for brain ischemia; 3) opioid receptors are widely expressed in the CNS; their role in modulating brain ischemia has to be elucidated.
MATERIALS AND METHODS

Drugs
SA (purity, ≥ 98%) was obtained from Apple Pharms (Asheville, NC). Norbinaltorphimine (nor-BNI; purity, ≥ 99.8%) was obtained from Tocris Bioscience (Minneapolis, MN). The pharmaceutical grade medications for animal studies were obtained from the pharmacy of the University of Pennsylvania. The remaining compounds were obtained from Sigma-Aldrich (St. Louis, MO).
Experimental Protocol
The animal protocol was approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. C57BL/6J mice (male) of 8-9 weeks (20-25 g) were purchased from the Jackson Laboratory (Bar Harbor, ME) and housed with free access to water and food. Animals were assigned to groups randomly, and all the tests were conducted in a blinded manner. The protocol consisted of two experiments. Experiment 1. This experiment aimed to determine the relationship between dose and effect. Intranasal SA was administered with various doses (0, 12.5, 25, and 50 μg/kg in dimethyl sulphoxide) 10 minutes after the initiation of reperfusion. The animals were randomly divided into the following five groups (n = 6 per group) (sham, MCAO, SA12.5, SA25, and SA50 groups). The infarct size and neurologic score were determined in a blinded manner. Experiment 2. This portion of the study aimed to study the specific role of KOR receptor and potential involvement of other pathologic process in brain ischemia. The reasonable dose of SA used in Experiment 2 was determined to be 50 μg/kg based on the data from Experiment 1. Mice were randomly divided into four groups (n = 18 per group): 1) sham group: mice in this group had the carotid arteries exposed without MCAO; 2) MCAO group: MCAO mice received intranasal administration of 25% DMSO 10 minutes after reperfusion; 3) SA50 group: MCAO mice received intranasal administration of SA (50 μg/kg) in DMSO 10 minutes after reperfusion; and 4) nor-BNI+SA50 group: MCAO mice received an IP injection of the KOR antagonist (nor-BNI) (0.05 mg/kg) 30 minutes before reperfusion and then intranasal administration of SA (50 μg/kg) in DMSO 10 minutes after reperfusion.
Mouse MCAO Model
The MCAO model was established using filament insertion as reported previously (4) . Mice were anesthetized with ketamine, xylazine, and acepromazine. After local infiltration with bupivacaine, the right common carotid artery was isolated and its branches were electrocoagulated. The proximal middle cerebral artery was occluded for 120 minutes by a 6-0 rounded tip nylon suture with length of 2 cm (Doccol, Sharon, MA), and blood flow was restored by removing the suture. During the procedure, the animals were placed over a feedback-controlled heating pad (Model TC-1000 Temperature Controller; CWE, Philadelphia, PA) to maintain the body temperature. After the surgery, mice were allowed to recover for 24 hours with adequate postoperative analgesia with meloxicam (5 mg/kg). In sham control animals, the carotid arteries were exposed without occlusion of the middle cerebral artery.
Neurologic Evaluation
Neurologic outcome was evaluated with the modified Grip test (5) (6) (7) , which uses a scale of 0-5 points, and Garcia scoring (8). The Garcia scoring system assigned 3-18 points and included the following six tests: spontaneous activity, forelimb walking, limb symmetry, climbing, side stroking, and vibris touch. Higher points indicated an improved neurologic outcome.
2, 3, 7-Triphenyltetrazolium Chloride (TTC) Staining and Infarct Area Measuring
Twenty-four hours after MCAO, TTC (Sigma, St. Louis, MO) staining (n = 6) was used to determine the infarct area (9) . The brain was cut into 2-mm thick coronal sections and then immersed in 2% TTC solution for half an hour at 37°C. The healthy tissue stained red as the tetrazolium reacted with the dehydrogenases in the viable cells, and the infarct tissue stained white because it lacked the enzymes with which the TTC reacts. The infarct area of each section was measured using an ImageJ analysis system (1.49v, National Institutes of Health, Bethesda, MD; http://rsb.info.nih. gov/ij/). The infarction rate was calculated as follows: infarct area in the right hemisphere/total area of the right hemisphere.
Immunohistochemistry Staining
For the histologic analysis, animals of each group were deeply anesthetized 24 hours after reperfusion. The brains were perfused with 10 mL of phosphate buffer saline and 20 mL of 4% paraformaldehyde, and then postfixed with formalin and embedded with paraffin. Brain sections were cut on a microtome (Leitz 1512, Stuttgart, Germany) into width of 5 μm thick. Immunohistochemistry labeling was performed as in a previous study with the primary antibody of rabbit anticleaved caspase-3 (number: 9661) (9). The staining was observed under a microscope (Olympus BX41, Center Valley, PA).
Evans Blue Extravasation
Evans blue extravasation observation was used to determine the BBB permeability. One hour after reperfusion, 4% Evans blue solution (0.1 mL; Sigma) was injected into the tail vein. Mice were perfused with PBS 24 hours after reperfusion, and brains were cut into coronal sections of 2 mm thick using a mouse coronal brain matrix (World Precision Instruments, Sarasota, FL) for imaging purposes. The concentration of the Evans blue Critical Care Medicine www.ccmjournal.org e1221 in the ischemic brain tissue was determined (expressed as μg/g of brain tissue) using the method previously reported (10) .
Protein Extraction and Western Blotting Analysis
The penumbra area was separated from the ischemic hemisphere and homogenized as reported previously (11) . The protein concentration was determined by the Pierce BCA Protein Assay Kit (Thermo Scientific, St. Louis, MO). Protein samples of 50-100 μg of each group was loaded onto 10% polyacrylamide gel, electrophoresed, and transferred to a nitrocellulose membrane. The nitrocellulose membranes were blocked and incubated with the primary antibody of rabbit anticleaved caspase-3 (number: 9661), rabbit anti TNF-α and rabbit anti-IL-10 (number: 12163) overnight at 4°C (Cell Signaling Technology, Danvers, MA). The nitrocellulose membranes were then processed with secondary antibodies (Santa Cruz Biotechnology, Dallas, TX) for 1 hour at room temperature. Immunoblots were detected using ECL Western Blotting Substrate (Thermo Fisher Scientific), and the membrane was detected by Carestream Molecular Imaging Software (Standard Edition; Carestream Health, Inc. Rochester, NY).
Fluorescent Labeling
KOR expression in the ischemic and nonischemic hemisphere of the brain was determined and compared using fluorescent labeling with the mouse monoclonal antibody against KOR (MO15098; Neuromics, Edina, MN). Double fluorescence labeling was conducted based on previous study (9) . Coronal sections were double stained with terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) and rabbit polyclonal antibody (1:200; Santa Cruz Biotechnology) of neuronal nuclear antigen (NeuN; neuronal marker), ionized calcium-binding adapter molecule 1 (iba1; microglia marker), and glial fibrillary acidic protein (GFAP) (astrocyte marker), and goat anti-rabbit IgG-tetramethylrhodamine isothiocyanate (red, fluorescein). The sections were cover-slipped and observed under a confocal microscope (Leica SP5, Buffalo Grove, IL). The images were processed with ImageJ analysis system (1.49v).
Data Analysis
Data were expressed as mean ± sem. The neurologic behavior test was compared by Kruskal-Wallis one-way analysis of variance (ANOVA) followed by multiple comparison procedures. Statistical significance was assured by ANOVA using a one-way ANOVA followed by the Tukey test. A probability value of p value less than 0.05 was considered statistically significant. Figure 1A shows representative samples of brains from mice that received different doses of SA. SA administration reduced infarction area dose-dependently as showed in Figure 1B . The neurologic outcome evaluation as shown in Figure 1C (Grip test) indicated that SA improved the neurologic outcome significantly in a dosedependent manner. The Garcia score was 12.2 ± 5.3, 13.5 ± 3.7, 13 ± 3.4, and 8.5 ± 0.4, respectively, in SA12.5, SA25, SA50, and MCAO groups (p < 0.05; SA groups compared with MCAO group). Both tests indicated significant improvement in neurologic outcome after SA administration. Figure 2A shows the Evans blue-stained brain section, reflecting the severity of the BBB damage. In the MCAO and KOR antagonist nor-BNI groups, intensive staining was seen in the cortex and striate areas in the ischemic area. SA treatment without the KOR antagonist showed significant less Evans blue staining in the ischemic area. SA administration significantly reduced Evans blue content in the SA50 group compared with that in the MCAO and nor-BNI+SA50 groups (Fig. 2B) . Nor-BNI given before the SA administration abolished the protective effects of SA.
RESULTS
SA Reduced Infarct Volume and Improved the Neurologic Score Dose-Dependently
SA Preserved the BBB
SA Decreased IL-10 and TNF-α in the Penumbra Area SA significantly reduced the production of IL-10. SA also reduced the levels of TNF-α, a cytokine that plays an important role in the inflammatory response in the hippocampus and cortex after ischemic injury. As shown in Figure 3, A and B , expression of both IL-10 and TNFα proteins increased significantly in the MCAO group compared with that in the sham group (#p < 0.05) at 24 hours but declined after treatment with SA ( Fig. 3, C and D) , and such reduction was blocked by nor-BNI (*p < 0.05).
Apoptosis Happens Mostly on Neurons in the Ischemic Hemisphere
As shown in Figure 4 , double immunofluorescence staining was conducted to determine which kind of cell undergoes apoptosis in ischemic hemisphere. Apoptotic cells (green) were shown as TUNEL-positive cells (Fig.  4A, 1-3 ). Neurons (red) were shown as NeuN-positive staining cells (Fig. 4B, 1) , astrocytes (red) were shown as GFAP-positive staining cells (Fig. 4B, 2) , and microglia (red) were shown as iba1-positive staining cells (Fig. 4B, 3) . From the merged images, we found that the apoptotic cells in the hippocampus colocalized with neurons ( Fig.  4C, 1 ) but rarely with astrocytes ( Fig. 4C, 2) and microglia (Fig.  4C, 3) . The same colocalization happened in the cortex as well (data not shown).
SA Inhibited the Apoptotic Process
The positive staining of activated caspase-3 was elevated in the border of the infarct area, which could also be referred as the penumbral area after MCAO injury. The penumbra is the area of the hypoperfused brain supplied by the collateral circulation that is still viable, but at risk for irreversible infarction if blood flow is not restored. The expression of activated caspase-3 was significantly inhibited after administration of SA in various regions of hippocampus, such as CA1 and CA2/3 and dentate gyrus, as well as in the cortex area (data not shown). Meanwhile, the inhibition was prominent both in immunohistochemistry staining and in western blot analysis (Fig. 5) . The quantitative study showed that the expression of caspase-3 was significantly decreased by SA, and such effect was blocked by KOR antagonist nor-BNI.
KOR Overexpressed in the Ischemic Penumbral Area After MCAO
The KOR expression increased in the ischemic penumbra cortex compared with that in the nonischemic area after MCAO (Fig. 6, A and B) . In particular, a high level of KOR expression was detected in the Purkinje cell layer of cerebellum (Fig. 6C) . An abundant expression in this region was described in guinea pigs (12) , whereas it was completely absent in rats (13) . Meanwhile, the KOR expression was also elevated in the ischemic hippocampus than that in the nonischemic area (Fig. 6D) . 
DISCUSSION
The following new findings were identified in this study: 1) significant KOR up-regulation was observed in the ischemic penumbra area after MCAO; 2) SA as a nonopioid and highly selective KOR agonist reduced infarct volume dose-dependently, protected the vascular integrity, and improved the neurological outcome; and 3) The underlying mechanism involved in the activation of KOR, inhibition of apoptosis, and reduction of inflammation factors such as IL-10 and TNF-α.
KOR agonists had a neuroprotective effect for ischemic injury in multiple animal models (14) (15) (16) . Rat, mouse, rabbit, or piglet hypoxia and ischemia models with pretreatment or posttreatment of KOR agonists were used for the observational studies (17) . Our previous study showed that administration of SA 30 minutes before, immediately, and 30 minutes after reperfusion preserved cerebrovascular autoregulation and was protective to the neurovascular unit in a piglet hypoxia and ischemia model (1) (2) (3) . Thus, KOR agonist must play a critical role in brain ischemic injury in animal models. This study not only further confirms the critical role of KOR agonist but also serves as an important study to elucidate the related mechanisms.
Our previous study indicated that KOR agonist dilates pial arteries via activation of nitric oxide synthase, adenosine triphosphate-sensitive potassium channels, and opioid receptors (2) . SA administration after global cerebral HI in piglet preserves autoregulation of pial artery via KOR activation and the extracellular signal-regulated kinases (ERK) activity inhibition (3). However, activation of ERK (increased ratio of phosphorylated ERK-to-ERK) may be related to protective effects of preconditioning in the pretreatment of SA on the pial artery autoregulation to hypotension and hypercapnia after HI in a piglet model (1) .
SA was traditionally used as an anti-inflammatory ingredient, and previous studies showed that SA could reduce lipopolysaccharide-induced paw edema and formalin-induced inflammation (18, 19) . Here, we investigated the possible antiinflammatory effect of SA in a well-established animal MCAO model. Microglia in the CNS can be activated after focal ischemia to serve as a key mediator in immune defense, which was also observed in this study (data not shown). Previous studies have shown that TNF-α protein, released from microglia under hypoxic ischemia (20) , was related to the BBB disruption as it can damage the tight junction (21) . Therefore, the protection of BBB shown from Evans blue extravasation observation might be attributed to the inhibition of the production of TNF-α released by microglia. In this study, ischemia increased the levels of IL-10, which is a regulatory cytokine limiting the inflammatory response. SA restored the level of IL-10 to levels similar to those seen in the sham group. Based , 1) . However, the apoptotic positive cells in hippocampus rarely colocalized with astrocyte (red) shown as glial fibrillary acidic protein (GFAP)-positive staining (B, 2) and also rarely colocalized with microglia (red) shown as ionized calciumbinding adapter molecule 1 (iba1)-positive staining (B, 3). C was the merger of A and B. The merged images indicated that the apoptotic cells in the hippocampus colocalized with neurons (yellow; C, 1) but rarely with astrocytes (C, 2) and microglia (C, 3). Scale bars indicated 50 μm. MCAO = middle cerebral artery occlusion. on this observation, SA might intercept the inflammatory initiation at a converging point downstream to serve as an antiinflammation molecule.
In contrast to necrosis, apoptosis occurs in the ischemic penumbra zone, where reperfused blood flow reduces the degree of hypoxia after several hours or days. Apoptotic induction might be mediated by increasing the proapoptotic factors or decreasing the antiapoptotic factors (22, 23) . In ischemic stroke, the caspase family is important in the brain ischemic injury-induced apoptosis of neuronal cells. Apoptosis happens mostly in neuronal cells instead of in microglia and astrocytes, which is shown by our double immunofluorescence staining. Caspase-3 can be activated through extrinsic and intrinsic signal pathways and is the main executioner in ischemic stroke animal models (24, 25) . Both immune staining and western blot showed that administration of SA decreased caspase-3 activation after the brain ischemia. Thus, it is likely that KOR agonist reduced the ischemic injury-induced apoptosis through inactivation of initiator of caspase. The neuroprotection of SA was induced by inhibition of apoptosis to prevent some neurons from transitioning into infarct and decreasing the overall infarct volume.
Behavioral improvement is the key endpoint and judgment of the potential of a drug in preclinical stroke studies. In this study, animals after MCAO injury showed impaired neurologic behavior. After the administration of SA, the neurologic outcome improved dose-dependently.
KOR expression increased in the ischemic penumbra area instead of the core area, suggesting that the KOR played important roles in the process of ischemic brain injury and repair. The activation of KOR might also be related to the survival of the brain tissue in the penumbra instead of core area after MCAO. However, the duration for this endogenous up-regulation of KOR and the subsequent pathway needs to be investigated in future studies.
It has been demonstrated that the neurologic protective effects of KOR agonists are sex specific (26) . In this study, only male mice were used to avoid the effects of estrogen. Sex-specific effects will be investigated in future studies. Previous studies demonstrated that BRL 52537 (a selective KOR agonist) at certain dosage showed neuroprotection in male but not in female rats, which highlighted the importance of using both sexes in animal models of experimental ischemia (27) . Most of the compounds that proved effective in the short-term clinical investigation failed in long-term clinical observation (28) . We only used short-term (24 hr) observation for the neurologic outcome evaluation. Thus, for validation and potential for clinical translation, long-term study is necessary to confirm the neuroprotective effect of KOR agonist. Also, we did not differentiate whether it is protective to ischemia or to the reperfusion injury, which needs a permanent ischemic animal model to induce only ischemic injury. 
